Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.

Cardiovasc Diabetol · 2022 · PMC9166572 · PMID 35658864

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Nonetheless, HHF did not reach statistical significance in this subgroup analysis as the event rates in the metformin-SGLT2i combination and SGLT2i monotherapy exposure periods were rather small.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.